Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2020 06:30 ET | Source: NKMax America

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy

Proof of Concept study to establish safety and recommended dose of Affimed’s innate cell engager (ICE®) AFM24 in combination with NKMax America’s Natural Killer (NK) cells in solid tumorsPre-clinical...
September 08, 2020 19:00 ET | Source: NKMax America

NKMax America Announces a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer

SANTA ANA, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
August 31, 2020 14:21 ET | Source: NKMax America

NKMax America Receives FDA Clearance to Amend its Current Phase I Monotherapy Trial to Include an Additional New Cohort of SNK01 + Checkpoint Inhibitor in Refractory Solid Tumors

SANTA ANA, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's innate immune system through the development of Natural Killer (NK)...
June 02, 2020 08:00 ET | Source: NKMax America

NKMax America Receives FDA Clearance of IND for Phase I/2a Trial of their Natural Killer Cell Therapy (SNK01) in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced/Metastatic HER2- or EGFR- Expressing Cancers

SANTA ANA, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
May 29, 2020 15:19 ET | Source: NKMax America

NKMax America Presents Promising Clinical Research Findings at 2020 ASCO Virtual Conference

SANTA ANA, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
April 30, 2020 08:00 ET | Source: NKMax America

NKMax America To Present Data from its Natural Killer Cell Immunotherapy Clinical Program at the ASCO20 Virtual Scientific Program

SANTA ANA, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
March 31, 2020 07:30 ET | Source: NKMax America

NKMax America Announces Acceptance of Three Abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting

SANTA ANA, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
March 17, 2020 20:00 ET | Source: NKMax America

NKMax America to Present at the Upcoming NIH-AACR Cancer, Autoimmunity, and Immunology Conference

SANTA ANA, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
March 09, 2020 16:01 ET | Source: NKMax America

NKMax America to Present at Immuno-Oncology Summit Europe 2020

SANTA ANA, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell...
March 03, 2020 07:00 ET | Source: NKMax America

NKMax America to Present Corporate Overview at the Cowen & Company 40th Annual Health Care Conference

SANTA ANA, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...